- Home
- KURA vs IMNM Comparison
KURA vs IMNM Comparison
Compare KURA & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- IMNM
- Stock Information
- Founded
- KURA 2014
- IMNM 2006
- Country
- KURA United States
- IMNM United States
- Employees
- KURA N/A
- IMNM N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- KURA Health Care
- IMNM Health Care
- Exchange
- KURA Nasdaq
- IMNM Nasdaq
- Market Cap
- KURA 793.2M
- IMNM 747.7M
- IPO Year
- KURA N/A
- IMNM 2020
- Fundamental
- Price
- KURA $9.48
- IMNM $12.01
- Analyst Decision
- KURA Strong Buy
- IMNM Strong Buy
- Analyst Count
- KURA 10
- IMNM 5
- Target Price
- KURA $30.13
- IMNM $28.60
- AVG Volume (30 Days)
- KURA 2.9M
- IMNM 803.1K
- Earning Date
- KURA 11-07-2024
- IMNM 11-13-2024
- Dividend Yield
- KURA N/A
- IMNM N/A
- EPS Growth
- KURA N/A
- IMNM N/A
- EPS
- KURA N/A
- IMNM N/A
- Revenue
- KURA N/A
- IMNM $10,129,000.00
- Revenue This Year
- KURA N/A
- IMNM N/A
- Revenue Next Year
- KURA $106.66
- IMNM N/A
- P/E Ratio
- KURA N/A
- IMNM N/A
- Revenue Growth
- KURA N/A
- IMNM N/A
- 52 Week Low
- KURA $9.40
- IMNM $7.76
- 52 Week High
- KURA $24.17
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- KURA 24.01
- IMNM 43.70
- Support Level
- KURA $9.40
- IMNM $12.99
- Resistance Level
- KURA $10.02
- IMNM $15.13
- Average True Range (ATR)
- KURA 0.46
- IMNM 0.93
- MACD
- KURA 0.10
- IMNM -0.16
- Stochastic Oscillator
- KURA 8.09
- IMNM 3.79
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.